Table 4.

Event-free survival rates in infant ALL.

Trial
Event-Free Survival
Reference
CCG 107   33% EFS @ 4 yrs   Reaman 
CCG 1883   39% EFS @ 4 yrs   
  3% t(4;11)*  
  50% other 11q23*  
  49% normal karyotype*  Reaman 
POG 8493   28% EFS @ 4 yrs   
  57% > 9 mos old @ diagnosis   
  18% < 9 mos old @ diagnosis   Frankel 
BFM 83, 86, 90   43% pEFS @ 6 yrs   
  53% Prednisone good response   
  15% Prednisone poor response   Dordelmann 
CLCG-EORTC 58881   41% EFS @ 4 yrs   Ferster 
UK ALL VIII, X, pilot   24% @ 6 yrs   
  40% > 6 mos old @ diagnosis   
  10% < 6 mos old @ diagnosis   Chessells 
Total Therapy X-XIII   EFS @ 5 yrs   
  56% (-)11q23/MLL rearrangements   
  6% (+)11q23/MLL rearrangements   
  42% > 6 mos old @ diagnosis   
  8% < 6 mos old @ diagnosis   Pui 
Dana Farber Consortium   54% DFS @ 50 mos   Silverman44  
Trial
Event-Free Survival
Reference
CCG 107   33% EFS @ 4 yrs   Reaman 
CCG 1883   39% EFS @ 4 yrs   
  3% t(4;11)*  
  50% other 11q23*  
  49% normal karyotype*  Reaman 
POG 8493   28% EFS @ 4 yrs   
  57% > 9 mos old @ diagnosis   
  18% < 9 mos old @ diagnosis   Frankel 
BFM 83, 86, 90   43% pEFS @ 6 yrs   
  53% Prednisone good response   
  15% Prednisone poor response   Dordelmann 
CLCG-EORTC 58881   41% EFS @ 4 yrs   Ferster 
UK ALL VIII, X, pilot   24% @ 6 yrs   
  40% > 6 mos old @ diagnosis   
  10% < 6 mos old @ diagnosis   Chessells 
Total Therapy X-XIII   EFS @ 5 yrs   
  56% (-)11q23/MLL rearrangements   
  6% (+)11q23/MLL rearrangements   
  42% > 6 mos old @ diagnosis   
  8% < 6 mos old @ diagnosis   Pui 
Dana Farber Consortium   54% DFS @ 50 mos   Silverman44  
*

includes CCG 107; Abbreviations: EFS, event-free survival; DFS, disease-free survival; CCG Children's Cancer Group; POG, Pediatric Oncology Group; BFM, Berlin-Frankfurt-Münster; CLCG-EORTC, Children's Leukemia Cooperative Group of the European Oncology Research and Treatment Cooperative

Close Modal

or Create an Account

Close Modal
Close Modal